Dbv Technologies S.A.: 5%+ holders

As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Dbv Technologies S.A. The largest reported stake is Baker Bros. Advisors LP's, at 9.99%. 25 filings are on record since August 12, 2025 (Schedule 13D/A, January 14, 2026).

Venrock Healthcare Capital Partners II, L.P. also filed stake reports on 1 other company ↓

Sell to companies like Dbv Technologies S.A? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: MPM BioImpact LLC · Sole voting: 18,331,420 · Shared voting: 0 · Sole dispositive: 18,331,420 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-06 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 18,288,220 · Sole dispositive: 0 · Shared dispositive: 18,288,220 · SCHEDULE 13G, 2026-08-06
• Filed 2026-05-15 · Holder: MPM BioImpact LLC · Percent: 8.8% · SCHEDULE 13G/A
• Filed 2026-05-13 · Holder: Adage Capital Management, L.P. · Percent: 7.31% · SCHEDULE 13G/A
• Filed 2026-05-13 · Holder: Artisan Partners Asset Management Inc. · Percent: 3.7% · SCHEDULE 13G/A

Dbv Technologies S.A. has 25 Schedule 13D or 13G filings on record since 2025-08-12. 6 holders' latest filing reports 5% or more of ordinary shares, nominal value 0.10 euro per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Dbv Technologies S.A. and the warning signs.

See Dbv Technologies S.A.'s free Snapshot Watch Dbv Technologies S.A.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Dbv Technologies S.A. and the records around it.

Dbv Technologies S.A. elsewhere on the record

• Form D filing Apr 2025
• Who owns it

Companies that share a holder

• Venrock Healthcare Capital Partners II, L.P. also filed stake reports on 1 other company: Cogent Biosciences, Inc. (Aug 2025)
• Bpifrance Participations S.A. also filed stake reports on 4 other companies: Cellectis S.A. (Nov 2026), Pasqal Holding SA (Sep 2026), Constellium SE (May 2026)
• MPM BioImpact LLC also filed stake reports on 4 other companies: Climb Bio, Inc. (Aug 2026), Context Therapeutics Inc. (Aug 2026), Forte Biosciences, Inc. (May 2026)

Want the whole picture on Dbv Technologies S.A.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Dbv Technologies S.A.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Dbv Technologies S.A. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   28 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Dbv Technologies S.A. by CUSIP 23306J309 and gives its principal executive office as 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of ordinary shares of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-08-06

Purpose of Transaction (Item 4)

Bpifrance Participations S.A.

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Bpifrance Participations sold the amount of Ordinary Shares on the date and at the price set forth below in open market transactions, except as noted otherwise. The sales of the Ordinary Shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this Schedule 13D. January 5, 2026: - 86,777 Ordinary Shares at a weighted average price of EUR3.02 per share (multiple transactions at prices ranging from EUR2.92 to EUR3.19, inclusive). All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. Except as set forth above, none of the Reporting Persons currently has any plans or proposals …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-07; the filing has the rest

Baker Bros. Advisors LP

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: On January 12, 2026, 667 and Life Sciences exercised 2,299,656 and 25,005,240 warrants, respectively, (each, a "BS Warrant") of the Issuer, at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a "Second Pre-Funded Warrant"), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175. The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants. Each of the Funds paid the exercise price for the BS Warrants using its working capital. The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a "Second Pre-Funded Warrant Share") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of Ordinary Shares, ADS or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-14; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Dbv Technologies S.A.

Who owns Dbv Technologies S.A.?

On this page, 6 holders' latest ownership filings report 5% or more of Dbv Technologies S.A.: Baker Bros. Advisors LP (9.99%, Schedule 13D/A, filed 2026-01-14), Janus Henderson Group Plc (8.8%, Schedule 13G/A, filed 2026-01-08), Adage Capital Management, L.P. (7.31%, Schedule 13G/A, filed 2026-05-13), Raymond Debbane (6.5%, Schedule 13G/A, filed 2026-05-05) and MPM BioImpact LLC (6.2%, Schedule 13G/A, filed 2026-08-14); 1 more is listed above.

Who are the largest shareholders of Dbv Technologies S.A.?

By the share each holder's latest filing reports, the largest holders of Dbv Technologies S.A. on this page are Baker Bros. Advisors LP (9.99%), Janus Henderson Group Plc (8.8%) and Adage Capital Management, L.P. (7.31%).

When did Baker Bros. Advisors LP buy into Dbv Technologies S.A.?

The filings give report dates, not purchase dates. The earliest filing from Baker Bros. Advisors LP on this page is the Schedule 13D/A, filed 2026-01-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 25 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Dbv Technologies S.A.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Dbv Technologies S.A.. With no account yet, you sign up free and land on the result.

• Get an alert when Dbv Technologies S.A. is mentioned again
• Find former Dbv Technologies S.A. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes